Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Aggarwal

Showing results (51-60 of 170) with videos related to

Pageof 17
Sort By:
Annals of the American Thoracic Society|September 28, 2016
How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision MakingMarilyn M Schapira, Charu Aggarwal, Scott Akers, et al.
JAMA Network Open|May 2, 2023
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With ImmunotherapyCharu Aggarwal, Rotem Ben-Shachar, Yinjie Gao, et al.
JAMA Oncology|June 4, 2023
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung CancerLova Sun, Benjamin Bleiberg, Wei-Ting Hwang, et al.
Oncotarget|October 17, 2015
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapyAnna K Brady, Jonathan D McNeill, Brendan Judy, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2021
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challengesCharu Aggarwal, Lukas Bubendorf, Wendy A Cooper, et al.
Clinical Lung Cancer|January 30, 2022
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of ImmunotherapyMelina E Marmarelis, Yu-Xiao Yang, Wei-Ting Hwang, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2020
Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation TherapyZhicheng Jiao, Hongming Li, Ying Xiao, et al.
American Journal of Clinical Oncology|April 22, 2016
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential TreatmentGenevieve Maquilan, Surbhi Grover, Eric Xanthopoulos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2018
Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung CancerSharyn I Katz, Mark Hammer, Stephen J Bagley, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
Pageof 17

Showing results (51-60 of 170) with videos related to

Sort By:
Pageof 17
Annals of the American Thoracic Society|September 28, 2016
How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision MakingMarilyn M Schapira, Charu Aggarwal, Scott Akers, et al.
JAMA Network Open|May 2, 2023
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With ImmunotherapyCharu Aggarwal, Rotem Ben-Shachar, Yinjie Gao, et al.
JAMA Oncology|June 4, 2023
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung CancerLova Sun, Benjamin Bleiberg, Wei-Ting Hwang, et al.
Oncotarget|October 17, 2015
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapyAnna K Brady, Jonathan D McNeill, Brendan Judy, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2021
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challengesCharu Aggarwal, Lukas Bubendorf, Wendy A Cooper, et al.
Clinical Lung Cancer|January 30, 2022
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of ImmunotherapyMelina E Marmarelis, Yu-Xiao Yang, Wei-Ting Hwang, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2020
Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation TherapyZhicheng Jiao, Hongming Li, Ying Xiao, et al.
American Journal of Clinical Oncology|April 22, 2016
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential TreatmentGenevieve Maquilan, Surbhi Grover, Eric Xanthopoulos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2018
Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung CancerSharyn I Katz, Mark Hammer, Stephen J Bagley, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
Pageof 17